Endo International PLC (NASDAQ:ENDP) (TSE:ENL) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 35,835,900 shares, a growth of 24.6% from the July 31st total of 28,757,700 shares. Currently, 17.7% of the company’s shares are short sold. Based on an average daily volume of 5,850,000 shares, the days-to-cover ratio is presently 6.1 days.
Several equities analysts have recently issued reports on ENDP shares. Zacks Investment Research lowered Endo International from a “buy” rating to a “hold” rating in a research report on Wednesday, May 15th. ValuEngine lowered Endo International from a “sell” rating to a “strong sell” rating in a research report on Tuesday, May 28th. BidaskClub lowered Endo International from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 18th. Cantor Fitzgerald decreased their target price on Endo International from $18.00 to $4.75 and set a “neutral” rating for the company in a research report on Wednesday, June 12th. Finally, Barclays started coverage on Endo International in a research report on Tuesday, June 11th. They set an “equal weight” rating and a $6.00 target price for the company. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $7.89.
Shares of ENDP traded down $0.09 on Thursday, hitting $3.96. The company’s stock had a trading volume of 8,553,003 shares, compared to its average volume of 4,906,761. The firm’s fifty day moving average price is $2.77 and its 200-day moving average price is $5.64. Endo International has a fifty-two week low of $1.97 and a fifty-two week high of $18.50. The firm has a market capitalization of $907.83 million, a price-to-earnings ratio of 1.37 and a beta of 1.23.
In other Endo International news, Director Roger H. Kimmel sold 34,951 shares of the business’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $3.93, for a total transaction of $137,357.43. Following the completion of the sale, the director now directly owns 148,309 shares of the company’s stock, valued at approximately $582,854.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.50% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. Meeder Asset Management Inc. grew its position in shares of Endo International by 47.1% in the 2nd quarter. Meeder Asset Management Inc. now owns 37,887 shares of the company’s stock valued at $156,000 after purchasing an additional 12,127 shares during the period. Factorial Partners LLC acquired a new position in Endo International during the 1st quarter worth approximately $193,000. Nordea Investment Management AB boosted its position in Endo International by 37.5% during the 1st quarter. Nordea Investment Management AB now owns 177,700 shares of the company’s stock worth $1,427,000 after acquiring an additional 48,500 shares during the last quarter. Arizona State Retirement System boosted its position in Endo International by 1.4% during the 2nd quarter. Arizona State Retirement System now owns 312,262 shares of the company’s stock worth $1,287,000 after acquiring an additional 4,167 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in Endo International by 61.2% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 3,063,703 shares of the company’s stock worth $12,622,000 after acquiring an additional 1,163,289 shares during the last quarter. Institutional investors and hedge funds own 95.80% of the company’s stock.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Recommended Story: Forex
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.